PHMMF (PHMMF) Stock Price & Analysis
PHMMF (PHMMF) rose 0.00% to USD 86.09 as of July 26, 2026 at 08:55 UTC, according to Nexqual real-time market data.
PHMMF last closed at USD 86.09; the session ranged USD 90.9–90.9 on volume of 100 shares. Market capitalization is $1.49B, with a 52-week range of USD 77.41–110.4 (PNK). Source: Nexqual, July 26, 2026 at 08:55 UTC.
Key Statistics (as of July 26, 2026 at 08:55 UTC)
| Price | USD 86.09 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 86.09 |
| Open | USD 90.9 |
| Day Range | USD 90.9 – 90.9 |
| 52-Week Range | USD 77.41 – 110.4 |
| Volume | 100 shares |
| Market Cap | $1.49B |
| Exchange | PNK |
Technical Analysis (PHMMF)
Nexqual's technical model rates PHMMF "SELL" based on 1 bullish and 4 bearish signals across 125 daily candles, as of July 26, 2026 at 08:55 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 35.89 (neutral) |
| vs SMA50 | Below (USD 93.06) |
| MACD | -1.14 (negative) |
Analyst Ratings (PHMMF)
Wall Street analysts rate PHMMF "None", per Nexqual as of July 26, 2026 at 08:55 UTC.
| Consensus Rating | None |
|---|
Earnings (PHMMF)
| Next Earnings Date | 2026-07-29 |
|---|---|
| Revenue Estimate | $44.69M |
Source: Nexqual, July 26, 2026 at 08:55 UTC.
Financials & Fundamentals (PHMMF)
| Total Revenue | $225.43M |
|---|---|
| Revenue Growth (YoY) | +10.40% |
| Gross Margin | +94.45% |
| Operating Margin | +1.45% |
| Profit Margin | +35.69% |
| ROE | +35.99% |
| Debt / Equity | 19.04 |
| Current Ratio | 3.07 |
| Total Cash | $167.85M |
| Total Debt | $47.54M |
| Free Cash Flow | $35.08M |
Source: Nexqual, July 26, 2026 at 08:55 UTC.
Financial Health Score (PHMMF)
Nexqual rates PHMMF's overall financial health "Strong" across five dimensions, as of July 26, 2026 at 08:55 UTC.
| Growth | Strong — Revenue +27% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 94%, operating 1% |
| Balance Sheet | Strong — $168M cash vs $48M debt, net cash position |
| Cash Flow | Strong — FCF $35M, 16% margin |
| Efficiency | Strong — ROE 36%, ROA 11.2% |
Ownership (PHMMF)
| Insider Ownership | +27.21% |
|---|---|
| Institutional Ownership | +9.56% |
| Shares Outstanding | 17.32M |
| Float | 13.42M |
Source: Nexqual, July 26, 2026 at 08:55 UTC.
Leadership (PHMMF)
PHMMF is led by Jose Maria Fernandez Sousa-Faro, Founder, Executive Chairman, CEO & President, per Nexqual as of July 26, 2026 at 08:55 UTC.
| Founder, Executive Chairman, CEO & President | Jose Maria Fernandez Sousa-Faro |
|---|---|
| Executive Vice-Chairman | Pedro Francisco Fernandez Puentes |
| Chief Financial Officer | María Luisa de Francia Caballero |
| General Counsel & Secretary of the Board of Directors | Juan Gomez Pulido |
| Communication Director | Lara Vadillo |
Major Backers & Investors (PHMMF)
Notable institutional backers of PHMMF include Goldman Sachs, DFA INVESTMENT TRUST CO-The Continental Small Company Series, Charles Schwab, according to Nexqual as of July 26, 2026 at 08:55 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Goldman Sachs | 0.44% |
| DFA INVESTMENT TRUST CO-The Continental Small Company Series | 0.34% |
| Charles Schwab | 0.14% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 2.06% |
| BlackRock | 0.89% |
| State Street | 0.31% |
Source: Nexqual, July 26, 2026 at 08:55 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| OXBDF | Oxford Biomedica PLC | USD 8 | ▲ 0.88% |
| PHGUF | Pharming Group NV | USD 1.3 | ▲ 0% |
| GNMSF | Genmab A/S | USD 274.5 | ▲ 0% |
| SBMFF | SINO BIOPHARMACEUTICAL | USD 0.64 | ▲ 0% |
| PHM.MC | PHARMA MAR, S.A. | EUR 79.3 | ▲ 0.51% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 26, 2026 at 08:55 UTC. This page is informational and not investment advice.